No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
4
Filings (14d)
Data as of 2026-07-15
2026-07-15
Prestige Consumer Healthcare Inc. issued $400 million of 6.250% senior notes due July 15, 2034, through its subsidiary Prestige Brands. The unsecured notes are guaranteed by the parent company and certain subsidiaries. The company can redeem the notes on or after July 15, 2029, or earlier with a make-whole premium, and must offer to buy them back at 101% in a change of control. The indenture includes standard covenants restricting additional debt, dividends, and asset sales.
Prestige Consumer Healthcare Inc. amended its Term Loan Credit Agreement on July 1, 2026, to allow borrowing up to $95 million to help finance its acquisition of LaCorium Health Australia and related companies.
Who are the top institutional investors holding PRESTIGE CONSUMER HEALTHCARE (PBH)?
Major stakeholders currently include BlackRock, Inc. ($437.9M), Ariel Investments, LLC ($253.3M), Vanguard Portfolio Management LLC ($166.2M). Based on the latest 13F filings, there are a total of 353 tracked investment funds and institutions maintaining positions in PBH.
What is the overall institutional sentiment toward PBH recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $110.9M, driven by 179 managers accumulating shares while 176 reduced their exposure.
Which institutions have been selling or reducing their PBH positions?
In the latest period, 130 funds trimmed their holdings, and 46 managers completely exited their positions. The aggregate reported sell value was $1.7B.
Are there any notable investors adding PBH to their portfolios?
Yes, buying activity remains notable. 46 institutions opened new positions in {ticker}, and 133 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.4B.